FDA records indicate that there are no current recalls for this drug.
Are you a medical professional?
Trending Topics
Analpram E Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
History
There is currently no drug history available for this drug.
Other Information
Analpram E® Cream 2.5% is a topical preparation containing hydrocortisone acetate 2.5% w/w and pramoxine hydrochloride 1 % w/w in a hydrolipid base containing cetostearyl alcohol, ceteth 20, mineral oil, white petrolatum, propylparaben, triethanolamine lauryl sulfate, citric acid, sodium citrate, and purified water.
Topical corticosteroids are anti-inflammatory and anti-pruritic agents. The structural formula, the chemical name, molecular formula and molecular weight for active ingredients are presented below.
hydrocortisone acetate Pregn-4-ene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-, (11-beta)-C23H32O6; mol. wt.: 404.50
pramoxine hydrochloride 4-(3-(p-butoxyphenoxy)propyl)morpholine hydrochloride C17H27NO3.HCl; mol.wt.: 329.87
Sources
Analpram E Manufacturers
- Sebela Pharmaceuticals Inc.
Analpram E | Marathon Pharmaceuticals, Llc
Start ISUPREL injection at the lowest recommended dose and increase the rate of administration gradually if necessary while carefully monitoring the patient. The usual route of administration is by intravenous infusion or bolus intravenous injection. In dire emergencies, the drug may be administered by intracardiac injection. If time is not of the utmost importance, initial therapy by intramuscular or subcutaneous injection is preferred.
Recommended dosage for adults with heart block, Adams-Stokes attacks, and cardiac arrest:Route of
Administration
Preparation of Dilution
Initial Dose
Subsequent
Dose Range*
Bolus
intravenous injection
Dilute 1 mL (0.2 mg) in 9 mL of Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP
0.02 mg to 0.06 mg
(1 mL to 3 mL of diluted solution)
0.01 mg to 0.2 mg
(0.5 mL to 10 mL of diluted solution)
Intravenous
infusion
Dilute 10 mL (2 mg) in 500 mL of 5% Dextrose Injection, USP
5 mcg/min.
(1.25 mL of diluted solution per minute)
Intramuscular
Use Solution undiluted
0.2 mg (1 mL)
0.02 mg to 1 mg
(0.1 mL to 5 mL)
Subcutaneous
Use Solution undiluted
0.2 mg (1 mL)
0.15 mg to 0.2 mg
(0.75 mL to 1 mL)Intracardiac
Use Solution undiluted
0.02 mg (0.1 mL)
* Subsequent dosage and method of administration depend on the ventricular rate and the rapidity with which the cardiac pacemaker can take over when the drug is gradually withdrawn.
There are no well-controlled studies in children to establish appropriate dosing; however, the American Heart Association recommends an initial infusion rate of 0.1 mcg/kg/min, with the usual range being 0.1 mcg/kg/min to 1 mcg/kg/min.
Recommended dosage for adults with shock and hypoperfusion states:Route of Administration
Preparation of Dilution†
Infusion Rate††
Intravenous infusion
Dilute 5 mL (1 mg) in 500 mL of 5% Dextrose Injection, USP
0.5 mcg to 5 mcg per minute
(0.25 mL to 2.5 mL of diluted solution)
† Concentrations up to 10 times greater have been used when limitation of volume is essential.
†† Rates over 30 mcg per minute have been used in advanced stages of shock. The rate of infusion should be adjusted on the basis of heart rate, central venous pressure, systemic blood pressure, and urine flow. If the heart rate exceeds 110 beats per minute, it may be advisable to decrease or temporarily discontinue the infusion.
Recommended dosage for adults with bronchospasm occurring during anesthesia:Route of
Administration
Preparation of Dilution
Initial Dose
Subsequent
Dose
Bolus
intravenous
injection
Dilute 1 mL (0.2 mg) in 9 mL of Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP
0.01 mg to 0.02 mg
(0.5 mL to 1 mL of diluted solution)
The initial dose may be repeated when necessary
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Such solution should not be used.
- Ferndale Laboratories, Inc.
Analpram E | Ferndale Laboratories, Inc.
Topical corticosteroids are generally applied to the affected area as a thin film three to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
- Ferndale Laboratories, Inc.
Analpram E | Ferndale Laboratories, Inc.
Topical corticosteroids are generally applied to the affected area as a thin film three to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Login To Your Free Account